Amendments to the Claims:

Listing of Claims:

1. (Currently Amended) An isolated compound for use in pharmaceutical therapy comprising SEQ ID NO:3, wherein said compound does not comprise SEQ ID NO:2, and contains 5-11 amino acids.

2. (Original) A compound according to claim 1, which is a polypeptide.

3. (Previously Amended) A compound according to claim 2, which comprises SEQ ID NO:4.

4. (Currently Amended) A pharmaceutical composition comprising a compound which comprises SEQ ID NO:3, wherein said compound does not comprise SEQ ID NO:2 , and contains 5-11 amino acids, and which composition comprises one or more pharmaceutically acceptable excipients.

5. (Currently Amended) ~~An effective amount of a~~ A pharmaceutical ~~compound~~ composition according to claim ~~1~~ 4 comprising an effective amount of said compound to inhibit leukocyte migration when administerd to a mammal.

6. (Currently Amended) A method of manufacture of a pharmaceutical composition, comprising:

combining a compound comprising SEQ ID NO:3, wherein said compound does not comprise SEQ ID NO:2, and which contains 5-11 amino acids, with a pharmaceutically acceptable excipient.

7. (Previously Amended) A method of treating or preventing an inflammatory response comprising administering to an animal an effective amount of a compound comprising SEQ ID NO:3, wherein said compound does not comprise SEQ ID NO:2.

8. (Original) The method according to claim 7, wherein the inflammatory response is gout, gouty arthritis, rheumatoid arthritis, asthma, reperfusion injury or damage, stroke, myocardial infarction, septic shock, or a skin disorder.

9. (Previously Added) A compound according to claim 1 which is effective in inhibiting leukocyte migration in a mammal.

10. (Previously Added) A compound according to claim 1 which is effective in treating or preventing an inflammatory response in a mammal.

11. (Previously Added) A compound according to claim 10 which is effective in treating or preventing inflammation in a mammal.